Evidence map›Paper›PMID 33251997›Full record

ArticleJournal of managed care & specialty pharmacy2020

Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide.

Anna Hung, Matthew Sinclair, Marion Hemmersbach-Miller, Daniel Edmonston, Christina Wyatt

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of managed care & specialty pharmacy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.0field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. [Research progress of antiviral treatment for patients with chronic hepatitis B combined with metabolic fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  2. The landscape of small-molecule prodrugs.Nature reviews. Drug discovery · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna HungDuke Clinical Research Institute and Department of Population Health Sciences, Duke University, Durham, NC.
Matthew SinclairDuke Clinical Research Institute and Department of Medicine, Division of Nephrology, Duke University, Durham, NC.
Marion Hemmersbach-MillerDuke Clinical Research Institute and Duke Division of Infectious Diseases, Duke University, Durham, NC.
Daniel EdmonstonDuke Clinical Research Institute and Department of Medicine, Division of Nephrology, Duke University, Durham, NC.
Christina WyattDuke Clinical Research Institute and Department of Medicine, Division of Nephrology, Duke University, Durham, NC.
Duke University · US

Funding

DUKE TRAINING GRANT IN NEPHROLOGYT32DK007731 · NIDDK · DUKE UNIVERSITY · PI CROWLEY, STEVEN D · 1995 to 2021
$3.6M
NIDDK NIH HHS T32 DK007731
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlanineAnti-HIV AgentsAntiviral AgentsComorbidityDrug ApprovalHIV InfectionsHumansPractice Patterns, Physicians'TenofovirUnited StatesUnited States Food and Drug AdministrationAlanineAnti-HIV AgentsAntiviral AgentsTenofovirtenofovir alafenamide

Identifiers

PMID33251997
PMCPMC8098116
OpenAlexW3107214735

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.